RxDoctor Payments Data

Maria Vegas, MD

Family Medicine · Miami, FLNPI 1982813861

Payments from drug & device makers

$2,118in general payments, 2019–2025

Across 59 payments — averaging $35.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$820
  • Pfizer$507
  • Boehringer Ingelheim$143
  • LEO Pharma Inc.$108
  • GSK$85
  • Lilly USA, LLC$71
  • plus $384 from 11 others

What the payments were for

  • Food & beverage$2,118100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,118 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$3,955
Medicare patients
16
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$52,047
EliquisApixaban21$12,276
FarxigaDapagliflozin Propanediol20$11,064
JanuviaSitagliptin Phosphate17$9,560
JardianceEmpagliflozin15$9,041
VascepaIcosapent Ethyl14$6,834
Diclofenac Sodium30$822
Fluticasone Propionate67$714
Atorvastatin Calcium91$648
Rosuvastatin Calcium64$516
Albuterol Sulfate HfaAlbuterol Sulfate27$495
Levothyroxine Sodium49$461
Ketoconazole39$442
Losartan Potassium61$434
Pantoprazole Sodium35$293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$36$52,04756 claims
PfizerEliquis$507$12,27621 claims
AstraZenecaFarxiga$820$11,06420 claims
Boehringer IngelheimJardiance$143$9,04115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →